What does this research mean for the field?

Tirzepatide provides significantly greater weight reduction and glycemic benefit compared to semaglutide in adults with overweight or obesity, though it is associated with a higher risk of serious adverse events. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To compare the efficacy and safety of tirzepatide versus semaglutide for weight reduction in adults with overweight or obesity across head-to-head investigations.

September 2, 2026Clinical ObesityOpen Access

Comparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta‐Analysis of Head‐to‐Head Studies

View Full Paper

Ask AI

Bookmark

Authors

GPGiovanna Pagani Paccola RORoberta Fernandes de Oliveira MMMatheus Menão Mochetti

Discussion

Member takes

Overview

Meta-analysis demonstrates greater weight loss with tirzepatide versus semaglutide in adults with overweight or obesity, indicating enhanced efficacy despite higher serious adverse event risks.

Key Points

To compare the efficacy and safety of tirzepatide versus semaglutide for weight reduction in adults with overweight or obesity across head-to-head investigations.
Systematic review and meta-analysis of 10 randomised controlled trials and observational studies including 41,381 participants with ≥ 24 weeks of follow-up.
The primary outcome was percentage weight change from baseline; secondary outcomes included absolute weight change, achievement of categorical weight-loss thresholds, HbA1c reduction, and adverse event profiles.
Tirzepatide led to greater percentage weight reduction (MD −4.28 percentage points; 95% CI −5.28 to −3.28; p < 0.00001) and greater absolute weight loss (MD −4.43 kg; 95% CI −5.56 to −3.30; p < 0.00001) than semaglutide.
Tirzepatide achieved superior HbA1c reductions (MD −0.29%; p = 0.0002) and higher odds of reaching ≥ 10%, ≥ 15%, and ≥ 20% weight loss thresholds, with no difference at the ≥ 5% threshold.
Treatment discontinuation rates due to adverse events were comparable (RR 1.28; p = 0.54), but serious adverse events occurred more frequently with tirzepatide (RR 1.83; p = 0.007).

Cite This Study

Paccola et al. (2026) studied this question.

synapsesocial.com/papers/6a97e25ec562ede874ec685d https://doi.org/10.1111/cob.70111

View Full Paper

Ask AI

Bookmark

September 2, 2026Clinical ObesityOpen Access

Comparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta‐Analysis of Head‐to‐Head Studies

View Full Paper

Ask AI

Bookmark

Authors

GPGiovanna Pagani Paccola RORoberta Fernandes de Oliveira MMMatheus Menão Mochetti

Discussion

Member takes

Overview

Meta-analysis demonstrates greater weight loss with tirzepatide versus semaglutide in adults with overweight or obesity, indicating enhanced efficacy despite higher serious adverse event risks.

Key Points

To compare the efficacy and safety of tirzepatide versus semaglutide for weight reduction in adults with overweight or obesity across head-to-head investigations.
Systematic review and meta-analysis of 10 randomised controlled trials and observational studies including 41,381 participants with ≥ 24 weeks of follow-up.
The primary outcome was percentage weight change from baseline; secondary outcomes included absolute weight change, achievement of categorical weight-loss thresholds, HbA1c reduction, and adverse event profiles.
Tirzepatide led to greater percentage weight reduction (MD −4.28 percentage points; 95% CI −5.28 to −3.28; p < 0.00001) and greater absolute weight loss (MD −4.43 kg; 95% CI −5.56 to −3.30; p < 0.00001) than semaglutide.
Tirzepatide achieved superior HbA1c reductions (MD −0.29%; p = 0.0002) and higher odds of reaching ≥ 10%, ≥ 15%, and ≥ 20% weight loss thresholds, with no difference at the ≥ 5% threshold.
Treatment discontinuation rates due to adverse events were comparable (RR 1.28; p = 0.54), but serious adverse events occurred more frequently with tirzepatide (RR 1.83; p = 0.007).

Cite This Study

Paccola et al. (2026) studied this question.

synapsesocial.com/papers/6a97e25ec562ede874ec685d https://doi.org/10.1111/cob.70111

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark